@article{fdi:010077935,
  title = {{H}epatitis {B} testing, treatment, and virologic suppression in {HIV}-infected patients in {C}ameroon ({ANRS} 12288 {EVOLCAM})},
  author = {{L}i{\'e}geois, {F}lorian and {B}oyer, {S}. and {E}ymard-{D}uvernay, {S}abrina and {C}arrieri, {P}. and {K}ouanfack, {C}. and {D}omyeum, {J}. and {M}aradan, {G}. and {D}ucos, {J}. and {M}poudi-{N}gole, {E}. and {S}pire, {B}. and {D}elaporte, {E}. and {K}uaban, {C}. and {V}idal, {L}aurent and {L}aurent, {C}hristian and {EVOLCAM} {S}tudy {G}roup,},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground{H}epatitis {B} is a major concern in {A}frica, especially in {HIV}-infected patients. {U}nfortunately, access to hepatitis {B} virus ({HBV}) testing and adequate treatment remains a challenge in the continent. {W}e investigated {HBV} testing, treatment, and virologic suppression in {HIV}-infected patients followed up as part of {C}ameroon's national antiretroviral programme.{M}ethods{A} cross-sectional survey was performed in adult patients receiving antiretroviral therapy ({ART}) in 19 hospitals in the {C}entre and {L}ittoral regions in {C}ameroon. {T}he proportions of patients tested for hepatitis {B} surface antigen ({HB}s{A}g) prior to the study were compared among all study hospitals using the {C}hi-square test. {T}he association of individual and hospital-related characteristics with {HBV} testing and virologic suppression was assessed using multilevel logistic regression models.{R}esults{O}f 1706 patients (women 74%, median age 42years, median time on {ART} 3.9years), 302 (17.7%) had been tested for {HB}s{A}g prior to the study. {T}he proportion of {HBV}-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p <0.001). {HBV} testing was lower in women (adjusted odds ratio [a{OR}] 0.64, 95% confidence interval [{CI}] 0.46-0.89, p =0.010) and higher in patients who initiated {ART} in 2010 or later (a{OR} 1.66, 95% {CI} 1.23-2.27, p <0.001). {O}f 159 {HB}s{A}g-positive patients at the time of the study (9.3%), only 97 (61.0%) received {T}enofovir + {L}amivudine (or {E}mtricitabine). {O}f 157 coinfected patients, 114 (72.6%) had a {HBV} viral load <10{IU}/m{L}. {HBV} suppression was higher in patients with a {HIV} viral load <300 copies/m{L} (a{OR} 3.46, 95% {CI} 1.48-8.09, p= 0.004) and lower in patients with increased {ALT} level (a{OR} 0.86 per 10{IU}/m{L} increase, 95% {CI} 0.75-0.97, p =0.019).{C}onclusions{A} substantial proportion of {HIV}/{HBV} coinfected patients were at higher risk of liver disease progression. {I}mproving the management of {HBV} infection in the routine healthcare setting in {A}frica is urgently required in order to achieve the 2030 elimination targets. {M}icro-elimination of {HBV} infection in people living with {HIV} could be an easier and cost-effective component than more widely scaling up {HBV} policies.},
  keywords = {{A}frica ; {HBV} ; {HIV} ; {T}esting ; {T}reatment ; {CAMEROUN}},
  booktitle = {},
  journal = {{BMC} {I}nfectious {D}iseases},
  volume = {20},
  numero = {1},
  pages = {[10 ]},
  year = {2020},
  DOI = {10.1186/s12879-020-4784-7},
  URL = {https://www.documentation.ird.fr/hor/fdi:010077935},
}